Breakthrough T1D

[9] The founding members formed the organization with the intent to find a cure for type 1 diabetes and its complications by supporting research.

[24] In 2008, Breakthrough T1D funded a clinical trial that demonstrated the efficacy of continuous glucose monitors (CGMs) in helping to manage blood sugar, with lower HbA1c levels and reduced rates of severe hypoglycemia.

[25] In the 1980s, Breakthrough T1D began funding basic research into disease-modifying therapies which can slow, halt, or reverse the progression of a disease.

[26] In 2019, Breakthrough T1D, in partnership with the NIH, funded a clinical trial that led to the 2022 FDA approval of teplizumab (Tzield), the first disease-modifying therapy for T1D.

[30] Breakthrough T1D advocates for federally-funded T1D research, facilitates the delivery of medical advancements and resources to the T1D community, and supports policies that help prevent, manage, and treat T1D, with an aim toward eventual development of a cure.

The program, which receives over $150 million in federal funding per year, provides resources and support for T1D research in cooperation with the NIH.

The aim of this advocacy is to ensure people have the freedom to choose treatment strategies that are appropriate for them, and to cover artificial pancreas/automated insulin delivery systems.

[42] Breakthrough T1D’s Government Day is an annual event where volunteer advocates tell their stories to illustrate the financial, medical, and emotional costs of type 1 diabetes to national leaders in the U.S. and help develop policy responses.

[43] In 2011, the FDA made it a priority to clarify the requirements for approval for such a closed-loop monitoring and drug delivery device for T1D, and announced it was preparing draft guidelines.

[48] One well-known care pack is the "Bag of Hope" which contains toys and story books for children recently diagnosed with T1D to help them adjust.